Results 171 to 180 of about 10,515,708 (302)

"Voice is the New Blood": a discourse analysis of voice AI health-tech start-up websites. [PDF]

Front Digit Health
Blatter A, Gallois H, Evangelista E, Bensoussan Y, Bridge2AI-Voice Consortium, Bélisle-Pipon JC.   +5 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Start up: A French program to support patients with pulmonary arterial hypertension during the adjustment of prostanoids to the individualized optimal dose. [PDF]

PLoS One
Bergot E, Fertin M, Dewavrin MG, Prévot G, Meijer J, Hakibilen C, Gruand L, Gauthier S, Todea A, Boukerzaza T, Jaïs X.   +10 more
europepmc   +1 more source

Quantitative assessment of the impact of standard agreement templates on multisite clinical trial start up time. [PDF]

J Clin Transl Sci, 2023
Lawrence CE, Bruce VNM, Salberg LD, Edwards T, Morales C, Palm M, Bernard GR.   +6 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Making data markets: Assetization, valuation, and proxy work in a digital health start-up. [PDF]

Soc Stud Sci
Donia J, Gibson J, Shaw JA.
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Swiss Life Sciences Start-ups – A 'tour d'horizon'

CHIMIA, 2014
Peter Burckhardt
doaj  

Threats & Trade-offs: A Start-up Simulation Game for Cybersecurity and Innovation Decision-Making. [PDF]

Inf Syst Front
Stsiampkouskaya K, Kundu O, Syrda J, Joinson A.   +3 more
europepmc   +1 more source

Impact of personality traits on start-up preparation of Hong Kong youths. [PDF]

Front Psychol, 2022
Zhuang J, Xiong R, Sun H.
europepmc   +1 more source